Home
↳
A pharmaceutical peptide manufacturer built on high-shear synthesis. Faster cycles, less material, lower cost.
What We Do
Complex
peptides
The cyclic, glycosylated and phosphorylated sequences that are slowest and most costly to make today.
High-shear synthesis
Fast mixing and controlled heat complete each coupling in seconds, on far less reagent.
Scale-out manufacturing
Capacity grows by adding standard reactors in parallel, not by building bigger plants.
The Problem
Demand is outpacing the capacity to make it.
The key is the chemistry.
The reason is clear: Conventional synthesis forces every step with large excesses of reagent and solvent, then throws most of it away. The longer and more complex the peptide, the worse it compounds, and the harder capacity is to add.
The Solution
Amidera's platform forces each reaction to completion in seconds, on a fraction of the reagent. Faster couplings, cleaner chains, and far less waste at every step.
[01]
Mix hard: Fast stirring at 1,200 rpm drives each coupling to completion in seconds, not minutes.
[02]
Heat, controlled: Holding 90°C speeds the reaction without degrading the growing chain.
[03]
Use less: Each coupling finishes on as little as 2.0 equivalents of amino acid.
The Evidence
Amidera's platform performs at levels demonstrated in published and peer-reviewed work.
Proven on the bench, not on paper.
A working reactor unit. A 29-residue glycopeptide synthesised in full. Results reproduced across triplicate runs, with resin integrity confirmed under the microscope.
The Model
Others scale one reactor up. We scale out.
Standard reactors running in parallel on shared feeds, under one control layer. Capacity grows by adding units, not by rebuilding the process.
A single working reactor unit.
Parallel arrays under unified control.
Heritage
A decade of chemistry, out of one of the world's leading peptide labs.
Amidera's high-shear platform began at the Hebrew University of Jerusalem, in the laboratory of Professor Mattan Hurevich, with Professor Chaim Gilon among its scientific minds. It is built on more than ten years of published, peer-reviewed research, licensed through Yissum, and protected by three patent families.
We make the ingredient today. We're building the platform around it.
Amidera is building a vertically integrated peptide platform. From advanced manufacturing through to a connected network of prescribers, compounding partners and specialty pharmacy, supported by an AI layer that matches capability to need across the chain.
The first layer is the Amidera Exchange: a verified network connecting prescribers with compounding pharmacies. No patient data, no prescriptions, no payments. Professionals connect, and everything clinical happens off the platform.
Let's Get to Work
